Form 4: BioXcel Therapeutics Executive Matthew T. Wiley Reports Stock Transactions
SEC Form 4
Chief Commercial Officer Matthew T. Wiley of BioXcel Therapeutics reports the acquisition and disposal of company stock and restricted stock units.
Summary
- On September 15, 2024, Matthew T. Wiley, Chief Commercial Officer of BioXcel Therapeutics, exercised 750 Restricted Stock Units (RSUs) and disposed of 215 shares of common stock on September 16, 2024, at a price of $0.6908 per share.
- Following these transactions, Wiley directly owns 4,033 shares of BioXcel Therapeutics common stock and 7,500 RSUs.
Sentiment
Score: 5
Explanation: This is a routine filing of stock transactions. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation and trading activities.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedule of the RSUs (25% after one year, then 6.25% quarterly) is a fairly standard practice.
- Trading plans under Rule 10b5-1 are frequently used by corporate insiders to avoid accusations of insider trading.
Stakeholder Impact
- The transactions themselves are unlikely to have a significant impact on stakeholders.
- However, consistent insider selling could be perceived negatively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023/03/15 | Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| 2023/12/14 | Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024/09/15 | Matthew T. Wiley exercised 750 Restricted Stock Units. |
| 2024/09/16 | Matthew T. Wiley disposed of 215 shares of common stock at $0.6908 per share. |
| 2024/09/17 | Date of Form 4 signature. |
Keywords
BioXcel Therapeutics, BTAI, Matthew T. Wiley, Chief Commercial Officer, Form 4, Stock Transaction, Restricted Stock Units, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.